News

Medtronic sales increasingly flee overseas as company chases growth

For all of the talk about how American healthcare reform and changes at the Food and Drug Administration will impact Medtronic Inc. (NYSE: MDT), perhaps it’s time to shift our focus beyond the United States. Judging by its latest earnings report, the country’s largest medical device maker certainly has. Overall, Medtronic said fiscal 2010 revenue […]

For all of the talk about how American healthcare reform and changes at the Food and Drug Administration will impact Medtronic Inc. (NYSE: MDT), perhaps it’s time to shift our focus beyond the United States.

Judging by its latest earnings report, the country’s largest medical device maker certainly has. Overall, Medtronic said fiscal 2010 revenue rose 8 percent to $15.8 billion from the previous year. Most of the growth came from international sales, which jumped 15 percent compared to just 4.2 percent in the United States.

There’s no question where Medtronic is heading. International sales now make up 41 percent of overall revenue. Assuming Medtronic maintains its current growth rates, international will overtake domestic operations in just four years. By 2015, international operations will account for 53 percent of the company’s overall revenue versus 47 percent in America.

Break down the numbers further and you will see Medtronic’s international sales by product category, with the exception of diabetes, grew at least twice as fast as its American counterparts. International cardiovascular revenue is growing about seven times faster than in the U.S.

United States

Cardiac Rhythm Management (pacemakers, ICDs) — 3.6 percent

Spinal — flat

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Cardiovascular (heart valves, peripheral stents) — 4 percent

Neurostimulation — 6.5 percent

Diabetes — 10 percent

International

Cardiac Rhythm Management — 7 percent

Spinal — 13.5 percent

Cardiovascular — 27 percent

Neurostimulation — 14.2 percent

Diabetes — 13 percent

Medtronic has seen the future and it looks quite foreign.